Moderna has a total of 1450 patents globally, out of which 248 have been granted. Of these 10068 patents, more than 49% patents are active. United States of America is where Moderna has filed the maximum number of patents, followed by Europe and Australia and it also seems reasonable as the biggest market for Moderna is USA. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Moderna.
Moderna was founded in 2010 by Derrick Rossi, Kenneth Chien, Noubar Afeyan, Robert Langer, Stephane Bancel and Timothy A. Springer. Moderna doing business in Biotechnology Industry. The company offers a range of products on Biotechnology, Genetics, Health Care, Medical and Pharmaceutical, etc. As of December 2021, Moderna has a market cap of $103.38 Billion.
Do read about some of the most popular patents of Moderna which have been covered by us in this article and also you can find Moderna patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Moderna patent portfolio.
How many patents does Moderna have?
Moderna has a total of 1450 patents globally. These patents belong to 277 unique patent families. Out of 1450 patents, 935 patents are active.
How many Moderna patents are Alive/Dead?
Worldwide Patents
Patent Families
How Many Patents did Moderna File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Moderna Applications Filed | Moderna Patents Granted |
| 2011 | 29 | – |
| 2012 | 73 | 1 |
| 2013 | 134 | – |
| 2014 | 132 | 6 |
| 2015 | 84 | 17 |
| 2016 | 217 | 19 |
| 2017 | 214 | 19 |
| 2018 | 232 | 38 |
| 2019 | 159 | 57 |
| 2020 | 103 | 41 |
| 2021 | 70 | 47 |
How Many Patents did Moderna File in Different Countries?
Countries in which Moderna Filed Patents
| Country | Patents |
| United States Of America | 381 |
| Europe | 185 |
| Australia | 109 |
| Japan | 108 |
| Hong Kong (S.A.R.) | 98 |
| Canada | 86 |
| China | 35 |
| Singapore | 29 |
| Korea (South) | 23 |
| Israel | 20 |
| Brazil | 18 |
| Mexico | 17 |
| Russian Federation | 14 |
| India | 13 |
| Germany | 11 |
| Taiwan | 9 |
| New Zealand | 6 |
| Malaysia | 6 |
| Argentina | 5 |
| Colombia | 4 |
| Chile | 4 |
| Viet Nam | 3 |
| Tunisia | 3 |
| Peru | 3 |
| Italy | 3 |
| United Kingdom | 3 |
| Indonesia | 3 |
| Philippines | 3 |
| Spain | 3 |
| South Africa | 3 |
| Denmark | 2 |
| France | 1 |
| Serbia | 1 |
| Portugal | 1 |
Where are Research Centers of Moderna Patents Located?
10 Best Moderna Patents
WO2013052523A1 is the most popular patent in the Moderna portfolio. It has received 264 citations so far from companies like CureVac, Obsidian Therapeutics, Novartis and New England Biolabs.
Below is the list of 10 most cited patents of Moderna:
| Publication Number | Citation Count |
| WO2013052523A1 | 264 |
| WO2013151671A1 | 257 |
| WO2013090648A1 | 241 |
| US8710200B2 | 229 |
| WO2013039857A1 | 221 |
| US20130245107A1 | 218 |
| US8822663B2 | 200 |
| US20140010861A1 | 199 |
| US20130244279A1 | 185 |
| US20120237975A1 | 185 |
Which Companies are using Moderna Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Moderna patent portfolio are Curevac, Translate Bio Inc and Factor Bioscience Inc.
List of the top forward citing Companies –
| Company | Number of Patents |
| Curevac | 10 |
| Translate Bio Inc | 10 |
| Factor Bioscience Inc | 3 |
| Base Pair Biotechnologies Inc | 2 |
| The General Hospital Corporation | 2 |
| Ribokine Llc | 2 |
| Dow Chemical Company | 2 |
| Boehringer Ingelheim Animal Health Usa Inc | 2 |
| Arcturus Therapeutics Inc | 2 |
| Nutrition & Biosciences Usa 2 Llc | 2 |
Count of 102 and 103 Type Rejections based on Moderna Patents
Top Moderna Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20130156849A1 | 8 |
| US9061059B2 | 6 |
| US8999380B2 | 6 |
| US9597380B2 | 6 |
| US20140010861A1 | 6 |
| US10124055B2 | 5 |
| US8710200B2 | 5 |
| US9192651B2 | 5 |
| US20120237975A1 | 4 |
| US10258698B2 | 3 |
| US20140200261A1 | 3 |
| US10323076B2 | 2 |
| US9149506B2 | 2 |
| US20130245107A1 | 2 |
| US20130266640A1 | 2 |
What Percentage of Moderna US Patent Applications were Granted?
Moderna (Excluding its subsidiaries) has filed 365 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 150 have been granted leading to a grant rate of 58.37%.
Below are the key stats of Moderna patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Moderna?
| Law Firm | Total Applications | Success Rate |
| Clark Elbing | 94 | 68.83% |
| Modernatx Inc | 86 | 77.08% |
| Cooley Llp | 67 | 78.79% |
| Dt Ward | 34 | 0.00% |
| Fish & Richardson | 28 | 75.00% |
| Nelson Mullins Riley & Scarborough | 26 | 52.00% |
| Sterne Kessler Goldstein & Fox | 11 | 18.18% |
| Finnegan Henderson Farabow Garrett & Dunner | 1 | 0% |
| Lando & Anastasi | 1 | 0.00% |
| Wolf Greenfield & Sacks | 1 | 100.00% |
“Leveraging the components of our Research Engine, we empower scientists across our ecosystem to conduct rational drug design and accelerate the pace of mRNA drug discovery.”
Using mRNA as a therapy is a very different strategy than using other drug classes to treat disease. It is extremely important in human biology. mRNA is a set of instructions that tells cells how to build and send proteins to different sections of the body.
mRNA medications use natural biological processes to express proteins and achieve the therapeutic effect needed. This opens the door to the treatment of a wide range of disorders, many of which are now untreatable with existing technology. Moderna thinks that mRNA has the potential to change the way medications are found, produced, and manufactured in ways that are unprecedented in our business in terms of breadth, speed, and scale.
Moderna’s mRNA RESEARCH ENGINE services enable it to advance new product ideas into development candidates through its drug discovery efforts, and includes infrastructure to enable rapid supply of thousands of preclinical mRNAs for research involving in vitro and in vivo experiments in order to speed programmes from concept to development candidate designation.
The mRNA DESIGN STUDIO from Moderna allows for the quick creation of numerous mRNAs. Moderna’s exclusive in-house digital application suite includes a Sequence Designer module that allows you to customise a full mRNA with ever-improving rule sets based on our mRNA design experience. To design each mRNA sequence, mRNA DESIGN STUDIO uses cloud-based computational resources to run various algorithms we’ve built. We can supply flexible computing capacity on demand thanks to cloud-based capacity, allowing the Research Engine to power parallel intake and design of various mRNA sequences.
EXCLUSIVE INSIGHTS COMING SOON!
What are Moderna’s key innovation segments?
What Technologies are Covered by Moderna?
The chart below distributes patents filed by Moderna in different countries on the basis of the technology protected in patents. It also represents the markets where Moderna thinks it’s important to protect particular technology inventions.
R&D Focus: How Moderna search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Moderna?